(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -36.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Arvinas's revenue in 2025 is $426,900,000.On average, 8 Wall Street analysts forecast ARVN's revenue for 2025 to be $21,531,949,110, with the lowest ARVN revenue forecast at $9,612,966,063, and the highest ARVN revenue forecast at $28,835,248,620. On average, 8 Wall Street analysts forecast ARVN's revenue for 2026 to be $11,119,727,327, with the lowest ARVN revenue forecast at $4,963,414,520, and the highest ARVN revenue forecast at $20,145,623,640.
In 2027, ARVN is forecast to generate $9,945,879,793 in revenue, with the lowest revenue forecast at $5,276,328,609 and the highest revenue forecast at $19,116,445,041.